VibroSense Dynamics: New Method for Assessment of Diabetic Neuropathy and Risk for Diabetic Foot Ulcers Presented at EASD

New Swedish study shows vibration can be used to measure diabetic
neuropathy

MUNICH–(BUSINESS WIRE)–A new Swedish study presented today at the European Association for
the Study of Diabetes (EASD) Annual Meeting in Munich offers a potential
breakthrough in the early detection of diabetic foot ulcers. Using a
measurement method called Multi-Frequency Vibrometry, the study shows a
strong correlation between decreased sensory perception in patients’
feet and risk of foot ulcers. It is estimated that 10% of people with
diabetes will have a diabetic ulcer at some point in their lives.
Furthermore, such ulcers precede more than 80% of amputations in people
with diabetes. The cost to the NHS in the UK alone is estimated at £650
million.

Led by Dr. Eero Lindholm, Consultant physician at Skånes University, the
study was selected by EASD for an oral presentation. Dr. Lindholm
and his group have studied patients with Type I Diabetes patients with
or without diabetic foot ulcers and compared them with healthy
volunteers. Sensory perception was tested using a specially developed
VibroSense Meter from Swedish medical device company Vibrosense. These
CE-marked instruments have been widely used for the last 10 years in
mining and other industries for detecting neuropathy in hands. As a
novel finding the data demonstrate that there is a strong correlation
between sensory loss at low frequent vibration and foot ulcers in
diabetic patients. Low frequency vibration has not been tested in
diabetic foot patients before and the results can indicate impairment of
sensory cells, Merkel cells and Meissner’s corpuscles as a consequence
of diabetes.

“The results are very promising and could lead to improved early
detection of diabetic foot ulcers. We have found a strong correlation
between foot ulcers and impaired tactile sensation at low vibration
frequencies. The study will continue for three years enabling us to
include more patients and broaden the body of evidence,” says Eero
Lindholm.

About VibroSense Dynamics AB (public)

VibroSense Dynamics AB (public) develops and markets efficient systems
for early detection and diagnosis of peripheral sensory neuropathy, i.e.
disease of large nerve fibers and nerve trunks in the legs and arms.

Contacts

VibroSense Dynamics AB
Richard Hayhurst
07711821527